Regencell Bioscience (RGC 2.52%) has a surprisingly large market cap of nearly $12 billion. The stock is up a shocking 21,000% over the past year. It started the 52-week period as a penny stock. Investors need to tread with caution and not get lured in by the massive price gain. What does Regencell Bioscience do? Regencell describes itself as an early stage bioscience company. That basically means...
Regencell Bioscience (RGC 2.52%) has a surprisingly large market cap of nearly $12 billion. The stock is up a shocking 21,000% over the past year. It started the 52-week period as a penny stock. Investors need to tread with caution and not get lured in by the massive price gain. What does Regencell Bioscience do? Regencell describes itself as an early stage bioscience company. That basically means it's researching drugs it believes may have promise, but it hasn't found anything yet. This is a high-risk area of the pharmaceutical sector that only the most aggressive investors should consider. If a bioscience company's research leads to a marketable product, its stock could take off. If it doesn't, the company could have trouble remaining a going concern. It is a bit of a moonshot type of investment. In order to justify buying a company like Regencell, you need to believe very strongly in the drug candidates that the company is researching. Most investors should stick to more established pharmaceutical companies that already have a portfolio of patented drugs. Regencell has spent 14 years examining "TCM" What's interesting about Regencell is that it has been operating since 2014 and still doesn't have a patented drug. Its focus is on traditional Chinese medicine, which the company usually just describes as TCM on its website. Expand NASDAQ : RGC Regencell Bioscience Today's Change ( -2.52 %) $ -0.61 Current Price $ 23.60 Key Data Points Market Cap $12B Day's Range $ 23.60 - $ 24.82 52wk Range $ 0.10 - $ 83.60 Volume 1.9K Avg Vol 457K The foreign company's annual report states the risks very clearly, summing the problem up in one sentence: We have no saleable products and have not generated any revenue from product sales. Unless you are deeply versed in TCM and have a strong belief that Regencell is on the verge of some breakthrough, you should probably avoid this stock. Why I would avoid Regencell (and what I would buy instead) I wouldn't touch Regencell with a 10-foo...
Key Points Regencell Bioscience is an early-stage bioscience company that has been working since 2014 to develop a marketable drug. The company's focus area is traditional Chinese medicine. 10 stocks we like better than Regencell Bioscience › Regencell Bioscience (NASDAQ: RGC) has a surprisingly large market cap of nearly $12 billion. The stock is up a shocking 21,000% over the past year. It start...
Key Points Regencell Bioscience is an early-stage bioscience company that has been working since 2014 to develop a marketable drug. The company's focus area is traditional Chinese medicine. 10 stocks we like better than Regencell Bioscience › Regencell Bioscience (NASDAQ: RGC) has a surprisingly large market cap of nearly $12 billion. The stock is up a shocking 21,000% over the past year. It started the 52-week period as a penny stock. Investors need to tread with caution and not get lured in by the massive price gain. What does Regencell Bioscience do? Regencell describes itself as an early stage bioscience company. That basically means it's researching drugs it believes may have promise, but it hasn't found anything yet. This is a high-risk area of the pharmaceutical sector that only the most aggressive investors should consider. Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue » If a bioscience company's research leads to a marketable product, its stock could take off. If it doesn't, the company could have trouble remaining a going concern. It is a bit of a moonshot type of investment. In order to justify buying a company like Regencell, you need to believe very strongly in the drug candidates that the company is researching. Most investors should stick to more established pharmaceutical companies that already have a portfolio of patented drugs. Regencell has spent 14 years examining "TCM" What's interesting about Regencell is that it has been operating since 2014 and still doesn't have a patented drug. Its focus is on traditional Chinese medicine, which the company usually just describes as TCM on its website. The foreign company's annual report states the risks very clearly, summing the problem up in one sentence: We have no saleable products and have not generated any revenue from product sales...
Palantir Technologies Inc. CEO Alex Karp did not mince words at a recent industry summit. He told Silicon Valley that trying to gut white-collar employment while also cutting off the military is a fast track to having your technology seized by the government. The remarks were delivered at the a16z American Dynamism Summit. "If Silicon Valley believes we're going to take everyone's white collar job...
Palantir Technologies Inc. CEO Alex Karp did not mince words at a recent industry summit. He told Silicon Valley that trying to gut white-collar employment while also cutting off the military is a fast track to having your technology seized by the government. The remarks were delivered at the a16z American Dynamism Summit. "If Silicon Valley believes we're going to take everyone's white collar jobs AND screw the military…If you don't think that's going to lead to the nationalization of our technology— you're retarded." -Alex Karp @palantirtech at @a16z American Dynamism Summit pic.twitter.com/4tslXaDP6t Katherine Boyle, co-founder of American Dynamism and general partner at a16z, posted a video clip of Karp’s comments on X on Wednesday. Don't Miss: Karp’s Blunt Warning To The Tech Industry “If Silicon Valley believes we’re going to take everyone’s white collar jobs AND screw the military…If you don’t think that’s going to lead to the nationalization of our technology — you’re retarded,” Karp said. Palantir CTO Shyam Sankar has also pushed back on the doom-and-gloom narrative around AI and jobs. Speaking on the All-In podcast in July 2025, Sankar argued AI gives workers “superpowers” rather than pink slips. The comment lands at a charged moment. The AI industry is navigating mounting tension between its commercial ambitions, its workforce impact, and its complicated relationship with the U.S. defense establishment. Anthropic CEO Had Already Sounded The Alarm On Jobs Karp’s remarks follow a warning issued in January by Anthropic CEO Dario Amodei. In a roughly 20,000-word essay, Amodei argued that the risks AI poses are not being taken seriously — and that a labor market “shock” unlike anything seen before is coming. See Also: Disney Was Built on Character IP — This Pre-IPO Company Is Using the Same Playbook “New technologies often bring labor market shocks, and in the past, humans have always recovered from them, but I am concerned that this is because these previous ...
Palantir Technologies Inc. CEO Alex Karp did not mince words at a recent industry summit. He told Silicon Valley that trying to gut white-collar employment while also cutting off the military is a fast track to having your technology seized by the government. The remarks were delivered at the a16z American Dynamism Summit. "If Silicon Valley believes we're going to take everyone's white collar job...
Palantir Technologies Inc. CEO Alex Karp did not mince words at a recent industry summit. He told Silicon Valley that trying to gut white-collar employment while also cutting off the military is a fast track to having your technology seized by the government. The remarks were delivered at the a16z American Dynamism Summit. "If Silicon Valley believes we're going to take everyone's white collar jobs AND screw the military…If you don't think that's going to lead to the nationalization of our technology— you're retarded." -Alex Karp @palantirtech at @a16z American Dynamism Summit pic.twitter.com/4tslXaDP6t Katherine Boyle, co-founder of American Dynamism and general partner at a16z, posted a video clip of Karp’s comments on X on Wednesday. Don't Miss: Karp’s Blunt Warning To The Tech Industry “If Silicon Valley believes we’re going to take everyone’s white collar jobs AND screw the military…If you don’t think that’s going to lead to the nationalization of our technology — you’re retarded,” Karp said. Palantir CTO Shyam Sankar has also pushed back on the doom-and-gloom narrative around AI and jobs. Speaking on the All-In podcast in July 2025, Sankar argued AI gives workers “superpowers” rather than pink slips. The comment lands at a charged moment. The AI industry is navigating mounting tension between its commercial ambitions, its workforce impact, and its complicated relationship with the U.S. defense establishment. Anthropic CEO Had Already Sounded The Alarm On Jobs Karp’s remarks follow a warning issued in January by Anthropic CEO Dario Amodei. In a roughly 20,000-word essay, Amodei argued that the risks AI poses are not being taken seriously — and that a labor market “shock” unlike anything seen before is coming. See Also: Disney Was Built on Character IP — This Pre-IPO Company Is Using the Same Playbook “New technologies often bring labor market shocks, and in the past, humans have always recovered from them, but I am concerned that this is because these previous ...
The Schwab US Dividend Equity ETF is trouncing the S&P 500 this year, reflecting investors’ renewed interest in “hard hat” sectors after years of obsession with Silicon Valley.
The Schwab US Dividend Equity ETF is trouncing the S&P 500 this year, reflecting investors’ renewed interest in “hard hat” sectors after years of obsession with Silicon Valley.
Palantir Technologies Inc. CEO Alex Karp did not mince words at a recent industry summit. He told Silicon Valley that trying to gut white-collar employment while also cutting off the military is a fast track to having your technology seized by the government. The remarks were delivered at the a16z American Dynamism Summit. "If Silicon Valley believes we're going to take everyone's white collar job...
Palantir Technologies Inc. CEO Alex Karp did not mince words at a recent industry summit. He told Silicon Valley that trying to gut white-collar employment while also cutting off the military is a fast track to having your technology seized by the government. The remarks were delivered at the a16z American Dynamism Summit. "If Silicon Valley believes we're going to take everyone's white collar jobs AND screw the military…If you don't think that's going to lead to the nationalization of our technology— you're retarded." -Alex Karp @palantirtech at @a16z American Dynamism Summit pic.twitter.com/4tslXaDP6t Katherine Boyle, co-founder of American Dynamism and general partner at a16z, posted a video clip of Karp’s comments on X on Wednesday. Don't Miss: Karp’s Blunt Warning To The Tech Industry “If Silicon Valley believes we’re going to take everyone’s white collar jobs AND screw the military…If you don’t think that’s going to lead to the nationalization of our technology — you’re retarded,” Karp said. Palantir CTO Shyam Sankar has also pushed back on the doom-and-gloom narrative around AI and jobs. Speaking on the All-In podcast in July 2025, Sankar argued AI gives workers “superpowers” rather than pink slips. The comment lands at a charged moment. The AI industry is navigating mounting tension between its commercial ambitions, its workforce impact, and its complicated relationship with the U.S. defense establishment. Anthropic CEO Had Already Sounded The Alarm On Jobs Karp’s remarks follow a warning issued in January by Anthropic CEO Dario Amodei. In a roughly 20,000-word essay, Amodei argued that the risks AI poses are not being taken seriously — and that a labor market “shock” unlike anything seen before is coming. See Also: Disney Was Built on Character IP — This Pre-IPO Company Is Using the Same Playbook “New technologies often bring labor market shocks, and in the past, humans have always recovered from them, but I am concerned that this is because these previous ...
何文田有鹹水管爆裂 行人路路陷致燈柱塌下 部分行車線受阻 To view this video please enable JavaScript, and consider upgrading to a web browser that supports HTML5 video 【有線新聞】何文田有鹹水管爆裂，行人路發生路陷，導致一條燈柱塌下。 從網上片段看到，鹹水夾雜沙泥湧到路面。下午3時許，忠...
何文田有鹹水管爆裂 行人路路陷致燈柱塌下 部分行車線受阻 To view this video please enable JavaScript, and consider upgrading to a web browser that supports HTML5 video 【有線新聞】何文田有鹹水管爆裂，行人路發生路陷，導致一條燈柱塌下。 從網上片段看到，鹹水夾雜沙泥湧到路面。下午3時許，忠孝街與孝民街交界有地下鹹水管爆裂，附近一段行人路面發生路陷，行人路一條燈柱塌下，阻礙部分行車線。警員現場指揮交通，水務署已派員進行搶修。
What happened According to a recent SEC filing, GOODNOW Investment Group, LLC added 131,723 shares of Maplebear (CART +3.56%) during the fourth quarter of 2025. The value of the position at quarter-end increased by $16.17 million, which includes both the new shares acquired and changes in the underlying stock price. What else to know The fund raised its investment in CART, which now represents 5.7...
What happened According to a recent SEC filing, GOODNOW Investment Group, LLC added 131,723 shares of Maplebear (CART +3.56%) during the fourth quarter of 2025. The value of the position at quarter-end increased by $16.17 million, which includes both the new shares acquired and changes in the underlying stock price. What else to know The fund raised its investment in CART, which now represents 5.78% of 13F AUM Top holdings after the filing: NYSE:CVNA: $299.67 million (28.0% of AUM) NYSE:GDDY: $92.04 million (8.6% of AUM) NASDAQ:EXPE: $74.53 million (7.0% of AUM) NYSE:W: $63.55 million (5.9% of AUM) NYSE:APTV: $57.25 million (5.3% of AUM) As of February 16, 2026, shares were priced at $36.30, down 27.4% over the past year and lagging the S&P 500 by 39.18 percentage points Company overview Metric Value Price (as of market close 2/13/26) $36.30 Market Capitalization $9.53 billion Revenue (TTM) $3.63 billion Net Income (TTM) $514.00 million Company snapshot Maplebear, doing business as Instacart, provides online grocery shopping services to households in North America. Maplebear provides online grocery shopping and delivery services, connecting consumers with personal shoppers for food, alcohol, consumer health, pet care, and ready-made meals. The company leverages a two-sided marketplace to connect consumers with personal shoppers, enabling rapid fulfillment of a wide range of household needs. The company operates through a mobile application and website, facilitating rapid fulfillment of household needs. What this transaction means for investors Maplebear, known to consumers as Instacart, operates at the intersection of grocery retail, logistics, and digital advertising. The platform connects households with local grocery stores and uses independent shoppers to fulfill and deliver orders. While online grocery demand surged during the pandemic, it has since stabilized as shoppers return to stores. As a result, investor focus has shifted from delivery growth to the mark...